-
1
-
-
33846457870
-
Cancer statistics 2007
-
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
-
(2007)
CA Cancer J Clin
, vol.57
, pp. 43-66
-
-
Jemal, A.1
Siegel, R.2
Ward, E.3
Murray, T.4
Xu, J.5
Thun, M.J.6
-
2
-
-
84971581087
-
Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
-
Non-small Cell Lung Cancer Collaborative Group
-
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
-
(1995)
BMJ
, vol.311
, pp. 899-909
-
-
-
3
-
-
1342268525
-
American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003
-
American Society of Clinical Oncology
-
Pfister DG, Johnson DH, Azzoli CG, et al.; American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353.
-
(2004)
J Clin Oncol
, vol.22
, pp. 330-353
-
-
Pfister, D.G.1
Johnson, D.H.2
Azzoli, C.G.3
-
4
-
-
0034069620
-
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
-
Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
-
(2000)
J Clin Oncol
, vol.18
, pp. 2095-2103
-
-
Shepherd, F.A.1
Dancey, J.2
Ramlau, R.3
-
5
-
-
22044445517
-
Erlotinib in previously treated non-small-cell lung cancer
-
National Cancer Institute of Canada Clinical Trials Group
-
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
-
(2005)
N Engl J Med
, vol.353
, pp. 123-132
-
-
Shepherd, F.A.1
Rodrigues Pereira, J.2
Ciuleanu, T.3
-
6
-
-
34247871456
-
Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: A systematic review and practice guideline
-
Noble J, Ellis PM, Mackay JA, Evans WK; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol 2006;1:1042-1058.
-
(2006)
J Thorac Oncol
, vol.1
, pp. 1042-1058
-
-
Noble, J.1
Ellis, P.M.2
MacKay, J.A.3
Evans, W.K.4
-
7
-
-
0032445062
-
A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex
-
Hanada M, Mizuno S, Fukushima A, Saito Y, Noguchi T, Yamaoka T. A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. Jpn J Cancer Res 1998;89: 1229-1238.
-
(1998)
Jpn J Cancer Res
, vol.89
, pp. 1229-1238
-
-
Hanada, M.1
Mizuno, S.2
Fukushima, A.3
Saito, Y.4
Noguchi, T.5
Yamaoka, T.6
-
8
-
-
0031786266
-
Cytotoxicity of amrubicin, A novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells
-
Yamaoka T, Hanada M, Ichii S, Morisada S, Noguchi T, Yanagi Y. Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. Jpn J Cancer Res 1998; 89:1067-1073.
-
(1998)
Jpn J Cancer Res
, vol.89
, pp. 1067-1073
-
-
Yamaoka, T.1
Hanada, M.2
Ichii, S.3
Morisada, S.4
Noguchi, T.5
Yanagi, Y.6
-
9
-
-
0031757797
-
Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin
-
Noguchi T, Ichii S, Morisada S, Yamaoka T, Yanagi Y. Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin. Jpn J Cancer Res 1998;89:1061-1066. (Pubitemid 28544783)
-
(1998)
Japanese Journal of Cancer Research
, vol.89
, Issue.10
, pp. 1061-1066
-
-
Noguchi, T.1
Ichii, S.2
Morisada, S.3
Yamaoka, T.4
Yanagi, Y.5
-
10
-
-
33646557308
-
Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial
-
DOI 10.1007/s10637-006-5937-2
-
Sawa T, Yana T, Takada M, et al. Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-smallcell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial. Invest New Drugs 2006;24:151-158. (Pubitemid 43723907)
-
(2006)
Investigational New Drugs
, vol.24
, Issue.2
, pp. 151-158
-
-
Sawa, T.1
Yana, T.2
Takada, M.3
Sugiura, T.4
Kudoh, S.5
Kamei, T.6
Isobe, T.7
Yamamoto, H.8
Yokota, S.9
Katakami, N.10
Tohda, Y.11
Kawakami, A.12
Nakanishi, Y.13
Ariyoshi, Y.14
-
11
-
-
34250684584
-
Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: A West Japan Thoracic Oncology Group (WJTOG) study
-
DOI 10.1007/s10637-007-9039-6
-
Takeda K, Takifuji N, Negoro S, et al. Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs 2007;25:377-383. (Pubitemid 46944847)
-
(2007)
Investigational New Drugs
, vol.25
, Issue.4
, pp. 377-383
-
-
Takeda, K.1
Takifuji, N.2
Negoro, S.3
Furuse, K.4
Nakamura, S.5
Takada, Y.6
Hoso, T.7
Hayasaka, S.8
Nakano, T.9
Araki, J.10
Senba, H.11
Iwami, F.12
Yamaji, Y.13
Fukuoka, M.14
Ikegami, H.15
-
12
-
-
0024536437
-
Optimal two-stage designs for phase II clinical trials
-
Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
-
(1989)
Control Clin Trials
, vol.10
, pp. 1-10
-
-
Simon, R.1
-
13
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors
-
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
-
(2000)
Journal of the National Cancer Institute
, vol.92
, Issue.3
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
Wanders, J.4
Kaplan, R.S.5
Rubinstein, L.6
Verweij, J.7
Van Glabbeke, M.8
Van Oosterom, A.T.9
Christian, M.C.10
Gwyther, S.G.11
-
14
-
-
34248670669
-
Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study
-
DOI 10.1007/s10637-006-9012-9
-
Yana T, Negoro S, Takada M, et al.; West Japan Thoracic Oncology Group. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs 2007;25:253-258. (Pubitemid 46774694)
-
(2007)
Investigational New Drugs
, vol.25
, Issue.3
, pp. 253-258
-
-
Yana, T.1
Negoro, S.2
Takada, M.3
Yokota, S.4
Takada, Y.5
Sugiura, T.6
Yamamoto, H.7
Sawa, T.8
Kawahara, M.9
Katakami, N.10
Ariyoshi, Y.11
Fukuoka, M.12
-
15
-
-
34547654536
-
Amrubicin for non-smallcell lung cancer and small-cell lung cancer
-
Kurata T, Okamoto I, Tamura K, Fukuoka M. Amrubicin for non-smallcell lung cancer and small-cell lung cancer. Invest New Drugs 2007;25: 499-504.
-
(2007)
Invest New Drugs
, vol.25
, pp. 499-504
-
-
Kurata, T.1
Okamoto, I.2
Tamura, K.3
Fukuoka, M.4
-
16
-
-
33644838068
-
Phase i and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer
-
Okamoto I, Hamada A, Matsunaga Y, et al. Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer. Cancer Chemother Pharmacol 2006; 57:282-288.
-
(2006)
Cancer Chemother Pharmacol
, vol.57
, pp. 282-288
-
-
Okamoto, I.1
Hamada, A.2
Matsunaga, Y.3
-
17
-
-
0034095853
-
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
-
The TAX 320 Non-small Cell Lung Cancer Study Group
-
Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-2362.
-
(2000)
J Clin Oncol
, vol.18
, pp. 2354-2362
-
-
Fossella, F.V.1
Devore, R.2
Kerr, R.N.3
-
18
-
-
2442661845
-
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
-
Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
-
(2004)
J Clin Oncol
, vol.22
, pp. 1589-1597
-
-
Hanna, N.1
Shepherd, F.A.2
Fossella, F.V.3
-
19
-
-
56249109644
-
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial
-
Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809-1818.
-
(2008)
Lancet
, vol.372
, pp. 1809-1818
-
-
Kim, E.S.1
Hirsh, V.2
Mok, T.3
-
20
-
-
56749131841
-
Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402
-
Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008;26:5401-5406.
-
(2008)
J Clin Oncol
, vol.26
, pp. 5401-5406
-
-
Inoue, A.1
Sugawara, S.2
Yamazaki, K.3
-
21
-
-
34247197121
-
Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301
-
Thoracic Oncology Research Group Study 0301
-
Onoda S, Masuda N, Seto T, et al.; Thoracic Oncology Research Group Study 0301. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 2006;24:5448-5453.
-
(2006)
J Clin Oncol
, vol.24
, pp. 5448-5453
-
-
Onoda, S.1
Masuda, N.2
Seto, T.3
|